Feline infectious peritonitis (FIP) is a fatal disease of cats caused by feline coronavirus. The goal of this study was to formally evaluate the administration of unlicensed, crowd-sourced antiviral GS-441524-like therapy for cats suspected to have feline infectious peritonitis (FIP). Members of a large social media support and GS-441524-like drug distribution group were surveyed via the Internet. Of the 393 analyzed surveys which met inclusion criteria, 73.7% of owners utilizing this therapy were from the United States. Only 8.7% of owners reported receiving significant help from their veterinarian in treating their cat. The mean cost of treatment was USD 4920. A majority of owners (88.2%) reported noticeable improvement in clinical signs within one week of initiating therapy. At the time of the survey, 96.7% (380 cats) were alive, with 54.0% of them considered cured and another 43.3% being monitored in the 12-week observation period. A total of 12.7% of the cats suffered a relapse of clinical signs of FIP, and 3.3% of the cats died despite GS-441524-like therapy. Reported complications were mostly related to owner administration of subcutaneous injections of the acidic GS-441524-like therapy, such as vocalization, pain, struggling, and injection-site wounds.
Hebei Weimiao Network Technology Co., Ltd. is a professional production and sales of chemical, cosmetic raw materials, plant extracts, cosmetics, pharmaceutical intermediates, metal materials manufacturers.
Founded in Hebei Province, the company has developed into a professional enterprise integrating
production, sales and technology development. At present, our products havebeen exported to Europe, the Middle East, Southeast Asia, the United States, Latin America, South America, Australia and other countries and regions. We will be your proud partner in China.
We will be a Chinese partner that make you proud , and we make efforts to provide you with professional and timely service.Look forward to establishing a good faith and friendly relationship with you.
China
